A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/mL at initial biopsy.


Journal

Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698

Informations de publication

Date de publication:
23 07 2021
Historique:
received: 07 01 2021
accepted: 25 06 2021
entrez: 24 7 2021
pubmed: 25 7 2021
medline: 27 1 2022
Statut: epublish

Résumé

The aim of this study was to identify a urine extracellular vesicle circular RNA (circRNA) classifier that could detect high-grade prostate cancer (PCa) of Grade Group (GG) 2 or greater. For this purpose, we used RNA sequencing to identify candidate circRNAs from urinary extracellular vesicles from 11 patients with high-grade PCa and 11 case-matched patients with benign prostatic hyperplasia. Using ddPCR in a training cohort (n = 263), we built a urine extracellular vesicle circRNA classifier (Ccirc, containing circPDLIM5, circSCAF8, circPLXDC2, circSCAMP1, and circCCNT2), which was evaluated in two independent cohorts (n = 497, n = 505). Ccirc showed higher accuracy than two standard of care risk calculators (RCs) (PCPT-RC 2.0 and ERSPC-RC) in both the training cohort and the validation cohorts. In all three cohorts, this novel urine extracellular vesicle circRNA classifier plus RCs was statistically more predictive than RCs alone for predicting ≥ GG2 PCa. This assay, which does not require precollection digital rectal examination nor special handling, is repeatable, noninvasive, and can be easily implemented as part of the basic clinical workflow.

Identifiants

pubmed: 34301266
doi: 10.1186/s12943-021-01388-6
pii: 10.1186/s12943-021-01388-6
pmc: PMC8299620
doi:

Substances chimiques

Biomarkers, Tumor 0
Cell-Free Nucleic Acids 0
RNA, Circular 0
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

96

Informations de copyright

© 2021. The Author(s).

Références

Urology. 2014 Jun;83(6):1362-7
pubmed: 24862395
Cell. 2019 Feb 7;176(4):831-843.e22
pubmed: 30735634
Lancet Oncol. 2012 Nov;13(11):e509-17
pubmed: 23117005
Mol Cancer. 2019 Jul 5;18(1):116
pubmed: 31277663
Eur Urol. 2005 Sep;48(3):386-99; discussion 398-9
pubmed: 15982797
BJU Int. 2016 Nov;118(5):706-713
pubmed: 26833820
Cell. 2019 Feb 7;176(4):869-881.e13
pubmed: 30735636
Eur Urol. 2016 Jul;70(1):45-53
pubmed: 25985884
Mol Cancer. 2018 Jul 23;17(1):103
pubmed: 30037351
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398
Am J Surg Pathol. 2017 Apr;41(4):e1-e7
pubmed: 28177964
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Ya-Di He (YD)

Centre of Physical Examination, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.

Wen Tao (W)

Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, Tianhe Road 600, Guangzhou, 510630, China.

Tao He (T)

Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, Tianhe Road 600, Guangzhou, 510630, China.

Bang-Yu Wang (BY)

Breast Surgery, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.

Xiu-Mei Tang (XM)

Centre of Physical Examination, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.

Liang-Ming Zhang (LM)

Department of Spine Surgery, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.

Zhen-Quan Wu (ZQ)

Department of Urology, Foshan First Municipal People's Hospital, Sun Yat-Sen University, Foshan, 528000, China.

Wei-Ming Deng (WM)

Department of Urology, The First Affiliated Hospital, University of South China, Hengyang, 421000, China.

Ling-Xiao Zhang (LX)

Department of Urology, The First Affiliated Hospital, Hainan Medical College, Haikou, 570102, China.

Chun-Kui Shao (CK)

Department of Pathology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.

Jing Zhou (J)

Department of Pathology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.

Li-Min Rong (LM)

Department of Spine Surgery, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.

Xin Gao (X)

Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, Tianhe Road 600, Guangzhou, 510630, China.

Liao-Yuan Li (LY)

Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, Tianhe Road 600, Guangzhou, 510630, China. liliaoy@mail.sysu.edu.cn.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH